The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).
 
Jason Alan Chesney
Consulting or Advisory Role - Amgen
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst)
Travel, Accommodations, Expenses - Amgen
 
Igor Puzanov
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Merck
 
Frances A. Collichio
Research Funding - Amgen; GlaxoSmithKline (Inst); Merck; Novartis
Other Relationship - ACGME
 
Mohammed M. Milhem
Honoraria - Amgen; Array BioPharma; Blueprint Medicines; Immunocore; Novartis; Trieza Therapeutics
Consulting or Advisory Role - Amgen; Array BioPharma; Blueprint Medicines; Immunocore; Novartis; Trieza Therapeutics
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Min Yi
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Sumita Bhatta
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Rubina Ismail
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Claus Garbe
Honoraria - Amgen; Bristol-Myers Squibb; MSD Oncology; NeraCare GmbH; Novartis; Philogen; Roche/Genentech; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; NeraCare GmbH; Novartis; Philogen; Roche/Genentech; Sanofi
Research Funding - Bristol-Myers Squibb; NeraCare GmbH; Novartis; Roche/Genentech
 
Parminder Singh
Consulting or Advisory Role - Bayer; Genentech/Roche; Janssen Oncology; Pfizer; Prometheus
Research Funding - EMD Serono
 
Janice M. Mehnert
Honoraria - EMD Serono; Pfizer/EMD Serono
Consulting or Advisory Role - Amgen; Array BioPharma; Array BioPharma; Boehringer Ingelheim; Merck Sharp & Dohme; Sanofi/Regeneron
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Incyte (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); polynoma (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Merck Sharp & Dohme
Other Relationship - Amgen; Array BioPharma; Boehringer Ingelheim; EMD Serono; Merck; Merck